Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.62 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.62 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4392734 | 0.98 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL11064695 | 0.84 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL10795479 | 0.82 | CHRNB2 (0.68) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL8369049 | 0.81 | CHRNA1 (0.43) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL28478794 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL24467444 | 0.80 | CHRNA1 (0.52) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL10480710 | 0.78 | CYP2D6 (0.46) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL1974393 | 0.78 | HTR1D (0.52) | SIGMAR1GAAGFERCYP1A2CYP2D6 | |
| Desnitroimidacloprid SCHEMBL29823081 | 0.77 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 | |
| SCHEMBL4102420 | 0.76 | HTR1D (0.55) | CHRNB2CHRNA4CHRNA1CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246483-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246483-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3256134-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | Enanta Pharmaceuticals, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2016130809-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20160229886-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229886-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160229886-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-08-11 | — | — | US | disclosed |
| CN-101253177-B | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| EP-1919921-B1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7494984-B2 | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-24 | — | — | US | disclosed |
| CN-101253177-A | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2008-08-27 | — | — | CN | disclosed |
| WO-2007027754-A1 | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229886-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CHRNB2 3475/4885CHRNA4 3646/4885CHRNA1 2430/4885 |
| US-20070049606-A1 | Bicyclic heterocycles as HIV-integrase inhibitors | CCNI, APOBEC3C, CDKN1A | CHRNB2 4609/4885CHRNA4 4225/4885CHRNA1 3302/4885 |
| US-10246483-B2 | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CHRNB2 3475/4885CHRNA4 3646/4885CHRNA1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.